P

Prothena Corp

D
PRTA
USD
0.18
(0.8372%)
Market Closed
18,984.00
Volume
-2.245
EPS
-
Div Yield
-23.063830
P/E
1,165,957,879.60
Market Cap
Today
0.8372%
1 Week
4.734%
1 Month
2.264%
6 Months
-13.591%
12 Months
-58.744%
Year To Date
-40.374%
All Time
-63.879%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SGMO
0.0617
(7.3584%)
USD
A
ALLO
0.025
(0.8681%)
USD
B
BLUE
-0.0046
(-0.9287%)
USD
C
CRSP
-0.11
(-0.2219%)
USD
E
EDIT
0.05
(1.292%)
USD
N
NTLA
0.41
(1.8214%)
USD
VRTX
VRTX
3.93
(0.8292%)
USD
B
BMRN
0.31
(0.4359%)
USD
GILD
GILD
0.015
(0.0179%)
USD
REGN
REGN
11.33
(0.9948%)
USD
I
INCY
1.67
(2.5625%)
USD

Title:
Prothena Corp

Sector:
Healthcare
Industry:
Biotechnology
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Do you need help or have a question?
Contact Us